Episode 150 hosts Dr Stephanie Manson-Brown (Plastic surgeon and an experienced leader in the biotech and pharmaceutical industry) Dr Manson-Brown is Head of Clinical Development and Vice President of Research and Development at Allergan Aesthetics, an AbbVie company. She and her team are responsible for global clinical trial development strategy for the aesthetics portfolio covering pharmaceuticals and devices. Stephanie also is the co-founder of the 'Science of Aging' platform, being born out of a desire to bring the latest developments from the field of aging science to the aesthetics arena and explore how these discoveries could potentially translate to aesthetic medicine. We explore: - What exactly R&D means? - How and why Dr Manson-Brown left her surgical career to work in big Pharma? - What Dr Manson-Brown's role is and what her duties are on a day to day basis? - What actually happens behind the scenes including how are new products and devices are developed? - How other companies are occasionally acquired to enhance the potential and scaling of a new products and bring them to a global market - What market research happens behind the scenes to drive the development of new products - How do Allergan Aesthetics decide what the market wants or needs? - Why some products never make it past the concept stage - What happens in a clinical trial, what are the phases? - Diversity in aesthetics & how Allergan Aesthetics are helping to represent our patient demographics better - What is 'digital science' and 'precision medicine'? - What happens once a product finishes in a clinical trial and is ready for market? (Working with the FDA, TGA and other global regulators) - What the Science of Aging meeting is? - What the future holds for aesthetics and will aging medicine supersede it?

ALL IA LINKS & CONTACT INFORMATION